carteolol has been researched along with Heart Failure in 3 studies
Carteolol: A beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent.
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Carteolol treatment increased beta-adrenergic receptor density, and the high carteolol dose restored SR Ca2+-ATPase and myofibrillar ATPase activities, along with creatine kinase, lactate dehydrogenase, aspartate transaminase, and ATP synthase activities, to normal." | 5.30 | Cellular and molecular remodeling in a heart failure model treated with the beta-blocker carteolol. ( Bristow, MR; DiSalvo, TG; Gwathmey, JK; Hajjar, RJ; Khan, F; Kim, CS; Matsumori, A, 1999) |
| "Fifteen patients with congestive heart failure underwent beta-blocker therapy." | 2.68 | Early reduction of neurohumoral factors plays a key role in mediating the efficacy of beta-blocker therapy for congestive heart failure. ( Akaishi, M; Anzai, T; Baba, A; Handa, S; Mitamura, H; Nishimura, H; Ogawa, S; Yoshikawa, T, 1996) |
| "Carteolol treatment increased beta-adrenergic receptor density, and the high carteolol dose restored SR Ca2+-ATPase and myofibrillar ATPase activities, along with creatine kinase, lactate dehydrogenase, aspartate transaminase, and ATP synthase activities, to normal." | 1.30 | Cellular and molecular remodeling in a heart failure model treated with the beta-blocker carteolol. ( Bristow, MR; DiSalvo, TG; Gwathmey, JK; Hajjar, RJ; Khan, F; Kim, CS; Matsumori, A, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yoshikawa, T | 1 |
| Handa, S | 1 |
| Anzai, T | 1 |
| Nishimura, H | 1 |
| Baba, A | 1 |
| Akaishi, M | 1 |
| Mitamura, H | 1 |
| Ogawa, S | 1 |
| Gwathmey, JK | 2 |
| Kim, CS | 1 |
| Hajjar, RJ | 2 |
| Khan, F | 1 |
| DiSalvo, TG | 1 |
| Matsumori, A | 1 |
| Bristow, MR | 1 |
| Washington, B | 1 |
| Butler, K | 1 |
| Doye, AA | 1 |
| Jang, M | 1 |
1 trial available for carteolol and Heart Failure
| Article | Year |
|---|---|
Early reduction of neurohumoral factors plays a key role in mediating the efficacy of beta-blocker therapy for congestive heart failure.
Topics: Adrenergic beta-Antagonists; Arginine Vasopressin; Atrial Natriuretic Factor; Carteolol; Female; Hea | 1996 |
2 other studies available for carteolol and Heart Failure
| Article | Year |
|---|---|
Cellular and molecular remodeling in a heart failure model treated with the beta-blocker carteolol.
Topics: Adenosine Triphosphate; Adenylyl Cyclases; Adrenergic beta-Antagonists; Animals; Blood Pressure; Bod | 1999 |
Heart function challenged with beta-receptor agonism or antagonism in a heart failure model.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Animals, Newborn; Blood Pressure; Ca | 2001 |